OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received

Related Keywords

Italy ,Japan ,United States ,Paris ,France General ,France ,French ,Italian ,Japanese ,American ,Alexandre Lebeaut ,Guillaume Van Renterghem Lifesci ,Thomas Guillot ,Alexis Peyroles ,Elise Chiffoleau ,Dominique Costantini ,Florence Portejoie ,Darren Opland ,European Patent Office ,Nantes University At Hospital ,Linkedin ,Twitter ,Boehringer Ingelheim ,Audit Committee ,American Society Of Hematology ,Trademark Office ,Lifesci Communications ,Veloxis Pharmaceuticals Inc ,Food Drug Administration ,Japanese Patent Office ,European Investment Bank ,Foundation Fo ,Nantes University Hospital ,Society For Immunotherapy Of Cancer ,American Association Of Cancer Research ,Data Monitoring Committee ,Us Food Drug Administration ,European Society For Medical Oncology ,Veloxis Pharmaceuticals ,Investigational New Drug ,Chief Executive Officer ,European Society ,Medical Oncology ,Independent Data Monitoring Committee ,B Cell Precursor Acute Lymphoblastic Leukemia ,American Society ,Fast Track Designation ,Drug Administration ,American Association ,Cancer Research ,Nantes University ,Science Advances ,Non Small Cell Lung Cancer ,Universal Registration Document ,Renterghem Lifesci Advisors ,Immunotherapeutics ,Reports ,021 ,Financial ,Results ,Major ,Progress ,Linical ,Programs ,Olid ,Cash ,Position ,Support ,Activities ,